ARDX Ardelyx FDA bad news. Last support for bounce

The FDA is unlikely to approve Ardelyx`s drug for dialysis patients.
Ardelyx received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought.

The most likely target is the 1.6usd support line from which it can bounce up.



ardelyxARDXfdafdaapprovalFundamental AnalysisTechnical IndicatorsSELLselloffsellsignalsignalsignalsTrend Analysis

Also on:

Disclaimer